BURR RIDGE, Ill., March 07, 2024 (GLOBE NEWSWIRE) -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ Experience, is exhibiting at the American Academy of Dermatology (AAD) annual meeting in San Diego March 8-12, and unveiling a groundbreaking new technology for the noninvasive treatment of common skin cancers.
SkinCure Oncology will unveil at AAD 2024 two new image-guided technology devices that, once granted marketing clearance by the U.S. Food and Drug Administration (FDA), will be the fourth generation of SRT.
GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging. Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions. Photoacoustic imaging, or PAI, will produce high contrast photosonic images of vascular and tissue analyses, with spatial resolution at penetration depths of 6 to 7 millimeters, offering a comprehensive view of lesion pathology, morphology, and disease stage.
"Imagine the possibilities when these two images combine, fusing lesion biology, physiology, and anatomic structure into a single data set that can be integrated with an advanced, AI-driven, ...